919 related articles for article (PubMed ID: 25592197)
21. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Leiter LA; Yoon KH; Arias P; Langslet G; Xie J; Balis DA; Millington D; Vercruysse F; Canovatchel W; Meininger G
Diabetes Care; 2015 Mar; 38(3):355-64. PubMed ID: 25205142
[TBL] [Abstract][Full Text] [Related]
22. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
Nauck M; del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S6-15. PubMed ID: 23529570
[TBL] [Abstract][Full Text] [Related]
23. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Bailey CJ; Gross JL; Hennicken D; Iqbal N; Mansfield TA; List JF
BMC Med; 2013 Feb; 11():43. PubMed ID: 23425012
[TBL] [Abstract][Full Text] [Related]
24. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
Diabetes Obes Metab; 2011 Oct; 13(10):928-38. PubMed ID: 21672123
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
Yang W; Han P; Min KW; Wang B; Mansfield T; T'Joen C; Iqbal N; Johnsson E; Ptaszynska A
J Diabetes; 2016 Nov; 8(6):796-808. PubMed ID: 26589253
[TBL] [Abstract][Full Text] [Related]
26. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Rosenstock J; Mathieu C; Chen H; Garcia-Sanchez R; Saraiva GL
Arch Endocrinol Metab; 2018 Aug; 62(4):424-430. PubMed ID: 30304106
[TBL] [Abstract][Full Text] [Related]
27. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S16-26. PubMed ID: 23529567
[TBL] [Abstract][Full Text] [Related]
28. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
[TBL] [Abstract][Full Text] [Related]
30. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
Schumm-Draeger PM; Burgess L; Korányi L; Hruba V; Hamer-Maansson JE; de Bruin TW
Diabetes Obes Metab; 2015 Jan; 17(1):42-51. PubMed ID: 25200570
[TBL] [Abstract][Full Text] [Related]
31. Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.
Skolnik N; Bonnes H; Yeh H; Katz A
Postgrad Med; 2016 May; 128(4):356-63. PubMed ID: 27043045
[TBL] [Abstract][Full Text] [Related]
32. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
Rosenstock J; Jelaska A; Zeller C; Kim G; Broedl UC; Woerle HJ;
Diabetes Obes Metab; 2015 Oct; 17(10):936-48. PubMed ID: 26040302
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Frias JP; Gonzalez-Galvez G; Johnsson E; Maaske J; Testa MA; Simonson DC; Dronamraju N; Garcia-Sanchez R; Peters AL
Diabetes Obes Metab; 2020 Jul; 22(7):1083-1093. PubMed ID: 32052516
[TBL] [Abstract][Full Text] [Related]
34. Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial.
Hong AR; Lee J; Ku EJ; Hwangbo Y; Kim KM; Moon JH; Choi SH; Jang HC; Lim S
Diabetes Res Clin Pract; 2015 Jul; 109(1):141-8. PubMed ID: 26003889
[TBL] [Abstract][Full Text] [Related]
35. Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566
[TBL] [Abstract][Full Text] [Related]
36. Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia.
Wan Seman WJ; Kori N; Rajoo S; Othman H; Mohd Noor N; Wahab NA; Sukor N; Mustafa N; Kamaruddin NA
Diabetes Obes Metab; 2016 Jun; 18(6):628-32. PubMed ID: 26889911
[TBL] [Abstract][Full Text] [Related]
37. Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
Ridderstråle M; Rosenstock J; Andersen KR; Woerle HJ; Salsali A;
Diabetes Obes Metab; 2018 Dec; 20(12):2768-2777. PubMed ID: 29961998
[TBL] [Abstract][Full Text] [Related]
38. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
Goring S; Hawkins N; Wygant G; Roudaut M; Townsend R; Wood I; Barnett AH
Diabetes Obes Metab; 2014 May; 16(5):433-42. PubMed ID: 24237939
[TBL] [Abstract][Full Text] [Related]
39. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
Wilding JP; Charpentier G; Hollander P; González-Gálvez G; Mathieu C; Vercruysse F; Usiskin K; Law G; Black S; Canovatchel W; Meininger G
Int J Clin Pract; 2013 Dec; 67(12):1267-82. PubMed ID: 24118688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]